Want to see SER full AI Analyst Report?
Serina Therapeutics (SER) Ratios
Serina Therapeutics Ratios
SER's free cash flow for Q2 2026 was $-6.68M. For the 2026 fiscal year, SER's free cash flow was decreased by $-28.00K and operating cash flow was $-6.68M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Mar 23 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.71 | 2.40 | 5.39 | 0.24 | 0.25 |
| Quick Ratio | 1.71 | 2.40 | 5.39 | 0.24 | 0.25 |
| Cash Ratio | 0.86 | 1.55 | 5.39 | 0.06 | 0.07 |
| Solvency Ratio | -2.73 | -1.76 | 0.13 | -0.13 | -0.08 |
| Operating Cash Flow Ratio | -5.04 | -7.24 | -1.75 | -0.21 | -0.25 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | -0.27 | -0.32 |
| Net Current Asset Value | $ -908.00K | $ -540.00K | $ -33.64M | $ -18.10M | $ -12.79M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.03 | 0.04 | 0.38 | 5.59 | 4.19 |
| Debt-to-Equity Ratio | -5.30 | 0.42 | -0.11 | -1.05 | -1.12 |
| Debt-to-Capital Ratio | 1.23 | 0.29 | -0.12 | 19.87 | 9.64 |
| Long-Term Debt-to-Capital Ratio | 1.23 | 0.00 | -0.10 | -1.56 | -1.05 |
| Financial Leverage Ratio | -187.86 | 10.49 | -0.28 | -0.19 | -0.27 |
| Debt Service Coverage Ratio | -88.87 | -19.94 | 10.60 | -0.34 | -0.17 |
| Interest Coverage Ratio | -112.78 | -32.41 | -5.61 | -142.99 | -527.31 |
| Debt to Market Cap | 0.01 | 0.00 | 0.03 | 0.85 | 0.31 |
| Interest Debt Per Share | 0.04 | 0.11 | 0.48 | 16.81 | 12.26 |
| Net Debt to EBITDA | 0.15 | 0.32 | -0.71 | -6.71 | -10.27 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | -246.43% | 97.15% | 100.00% | 100.00% |
| EBIT Margin | 0.00% | -19073.21% | 184.81% | -533.25% | -41.51% |
| EBITDA Margin | 0.00% | -18726.79% | 187.66% | -520.99% | -40.41% |
| Operating Profit Margin | 0.00% | -30442.86% | -99.24% | -454.07% | -53.68% |
| Pretax Profit Margin | 0.00% | -20012.50% | 167.11% | -536.42% | -41.61% |
| Net Profit Margin | 0.00% | -19894.64% | 167.11% | -536.42% | -41.61% |
| Continuous Operations Profit Margin | 0.00% | -20012.50% | 167.11% | -536.42% | -41.61% |
| Net Income Per EBT | 99.92% | 99.41% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 79.91% | 65.74% | -168.39% | 118.14% | 77.52% |
| Return on Assets (ROA) | -275.96% | -165.69% | 58.75% | -82.76% | -40.10% |
| Return on Equity (ROE) | 51843.24% | -1738.07% | -16.32% | 15.58% | 10.69% |
| Return on Capital Employed (ROCE) | -709.03% | -391.19% | -41.42% | 33.21% | 28.07% |
| Return on Invested Capital (ROIC) | -709.03% | -391.19% | -41.42% | -280.64% | -122.95% |
| Return on Tangible Assets | -275.96% | -165.69% | 58.75% | -107.16% | -40.10% |
| Earnings Yield | -98.56% | -30.22% | 4.55% | -12.61% | -3.02% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 125.00 | 121.57 |
| Payables Turnover | 0.00 | 0.26 | 0.16 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.05 | 2.34 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.01 | 0.35 | 0.15 | 0.96 |
| Working Capital Turnover Ratio | 0.00 | 0.01 | -4.44 | -0.07 | -0.62 |
| Cash Conversion Cycle | 0.00 | -1399.79 | -2352.22 | 2.92 | 3.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 2.92 | 3.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 1399.79 | 2352.22 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 2.92 | 3.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.76 | -2.33 | -0.29 | -1.92 | -2.09 |
| Free Cash Flow Per Share | -1.76 | -2.33 | -0.35 | -1.93 | -2.19 |
| Dividend Paid and CapEx Coverage Ratio | -304.32 | -778.95 | -4.91 | -214.38 | -20.76 |
| Capital Expenditure Coverage Ratio | -304.32 | -778.95 | -4.91 | -214.38 | -20.76 |
| Operating Cash Flow Coverage Ratio | -91.61 | -63.94 | -0.72 | -0.11 | -0.17 |
| Operating Cash Flow to Sales Ratio | 0.00 | -306.02 | -0.79 | -4.15 | -0.74 |
| Free Cash Flow Yield | -92.25% | -46.54% | -2.58% | -9.81% | -5.63% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -1.00 | -3.32 | 21.96 | -7.93 | -33.16 |
| Price-to-Sales (P/S) Ratio | 0.00 | 658.37 | 36.69 | 42.53 | 13.80 |
| Price-to-Book (P/B) Ratio | -526.02 | 57.52 | -3.58 | -1.24 | -3.54 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -1.08 | -2.15 | -38.82 | -10.20 | -17.78 |
| Price-to-Operating Cash Flow Ratio | -1.08 | -2.15 | -46.72 | -10.25 | -18.63 |
| Price-to-Earnings Growth (PEG) Ratio | -0.04 | 0.01 | -0.18 | 0.11 | 1.61 |
| Enterprise Value Multiple | -0.88 | -3.19 | 18.85 | -14.87 | -44.42 |
| Enterprise Value | 16.60M | 33.46M | 111.52M | 38.74M | 54.55M |
| EV to EBITDA | -0.88 | -3.19 | 18.85 | -14.87 | -44.42 |
| EV to Sales | 0.00 | 597.58 | 35.37 | 77.49 | 17.95 |
| EV to Free Cash Flow | -0.92 | -1.95 | -37.42 | -18.58 | -23.12 |
| EV to Operating Cash Flow | -0.92 | -1.95 | -45.04 | -18.67 | -24.24 |
| Tangible Book Value Per Share | -0.00 | 0.07 | -3.84 | -16.73 | -11.02 |
| Shareholders’ Equity Per Share | -0.00 | 0.09 | -3.84 | -15.95 | -10.98 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.01 | 0.37 | 0.46 | 2.82 |
| Net Income Per Share | -1.88 | -1.51 | 0.63 | -2.49 | -1.17 |
| Tax Burden | 1.00 | 0.99 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.01 | 1.05 | 0.90 | 1.01 | 1.00 |
| Research & Development to Revenue | 0.00 | 133.57 | 0.76 | 3.15 | 1.25 |
| SG&A to Revenue | 0.00 | 168.39 | 1.24 | 2.58 | 0.43 |
| Stock-Based Compensation to Revenue | 0.00 | 46.34 | 0.01 | 0.01 | 0.03 |
| Income Quality | 0.92 | 1.53 | -0.47 | 0.77 | 1.78 |
Currency in USD
